10x Genomics, Inc. (NASDAQ:TXG) Shares Sold by Advisors Asset Management Inc.

Advisors Asset Management Inc. trimmed its position in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 2.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 26,817 shares of the company’s stock after selling 674 shares during the quarter. Advisors Asset Management Inc.’s holdings in 10x Genomics were worth $606,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. SG Americas Securities LLC increased its position in shares of 10x Genomics by 604.9% during the second quarter. SG Americas Securities LLC now owns 101,344 shares of the company’s stock worth $1,971,000 after purchasing an additional 86,967 shares in the last quarter. Lecap Asset Management Ltd. purchased a new stake in 10x Genomics in the 3rd quarter valued at $877,000. Marshall Wace LLP purchased a new stake in 10x Genomics in the 2nd quarter valued at $689,000. Benjamin F. Edwards & Company Inc. grew its holdings in 10x Genomics by 10,124.9% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 44,785 shares of the company’s stock valued at $871,000 after buying an additional 44,347 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C purchased a new stake in 10x Genomics in the 2nd quarter valued at $11,612,000. 84.68% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

TXG has been the subject of a number of research analyst reports. Morgan Stanley lowered their price target on 10x Genomics from $50.00 to $46.00 and set an “overweight” rating for the company in a report on Tuesday, August 13th. Stephens reiterated an “overweight” rating and set a $30.00 price target on shares of 10x Genomics in a report on Thursday, October 10th. JPMorgan Chase & Co. lowered their price target on 10x Genomics from $20.00 to $14.00 and set a “neutral” rating for the company in a report on Wednesday, October 30th. UBS Group lowered their price target on 10x Genomics from $25.00 to $20.00 and set a “neutral” rating for the company in a report on Wednesday, October 30th. Finally, Leerink Partnrs upgraded 10x Genomics to a “strong-buy” rating in a report on Tuesday, September 3rd. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, 10x Genomics currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.19.

10x Genomics Price Performance

TXG stock opened at $15.48 on Thursday. The firm has a market capitalization of $1.87 billion, a P/E ratio of -10.12 and a beta of 1.87. The business’s 50-day moving average is $17.18 and its two-hundred day moving average is $19.71. 10x Genomics, Inc. has a 1 year low of $12.95 and a 1 year high of $57.90.

10x Genomics (NASDAQ:TXG) last issued its earnings results on Tuesday, October 29th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.04. 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. The business had revenue of $151.65 million for the quarter, compared to analyst estimates of $158.84 million. During the same quarter last year, the company earned ($0.51) EPS. The business’s quarterly revenue was down 1.3% on a year-over-year basis. On average, analysts expect that 10x Genomics, Inc. will post -1.4 EPS for the current year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.